GSK's vaccine against respiratory syncytial virus (RSV) is one of ... with the final results of Pfizer's study and as the data from both studies is subjected to scrutiny. The two companies say ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

The delayed meeting of the CDC's main vaccines advisory committee has taken place, with new recommendations on respiratory syncytial virus (RSV) vaccines that do away with restrictions imposed ...

PFE Pfizer Inc. 0 0.00% 0.00% JNJ Johnson & Johnson 0 0.00% 0.00% ABBV AbbVie Inc. 0 0.00% 0.00% Compare Similar to MRK ETFs Holding MRK Seeking Alpha - Power to Investors Power to Investors ...

Hearst Television participates in various affiliate marketing programs, which means we may get paid commissions on editorially chosen products purchased through our links to retailer sites.

Medical news, education and information for physicians and health care professionals, presented by specialty and topic. From Healio and the Wyanoke Group.